{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:37:23Z","timestamp":1791308243448,"version":"4.3.1"},"reference-count":129,"publisher":"Informa UK Limited","issue":"1","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Anti-infective Therapy"],"published-print":{"date-parts":[[2015,1,2]]},"DOI":"10.1586\/14787210.2015.990382","type":"journal-article","created":{"date-parts":[[2014,12,9]],"date-time":"2014-12-09T01:15:25Z","timestamp":1418087725000},"page":"9-27","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":42,"title":["Isavuconazole, a broad-spectrum triazole for the treatment of systemic fungal diseases"],"prefix":"10.1586","volume":"13","author":[{"given":"Seyedmojtaba","family":"Seyedmousavi","sequence":"first","affiliation":[{"name":"Department of Medical Microbiology and Infectious Diseases, Erasmus MC,","place":["The Netherlands"]},{"name":"Department of Medical Microbiology, Radboudumc,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul E","family":"Verweij","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, Radboudumc,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan W","family":"Mouton","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Infectious Diseases, Erasmus MC,","place":["The Netherlands"]},{"name":"Department of Medical Microbiology, Radboudumc,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2014,12,8]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0b013e328335a755"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12539"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12563"},{"issue":"8","key":"e_1_3_3_5_1","first-page":"1068","article-title":"The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study","volume":"91","author":"Pagano L","year":"2006","unstructured":"Pagano L, Caira M, Candoni A, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 2006;91(8):1068-75","journal-title":"Haematologica"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1086\/319985"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2009.01391.x"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm428"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.4065\/mcp.2011.0247"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11046-010-9324-3"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S51340"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2012.683859"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn076"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2011.08.006"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.2010.01996.x"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01530-08"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01512-07"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki399"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00636-13"},{"key":"e_1_3_3_20_1","unstructured":"Seyedmousavi S Rijs AJ Melchers WJ et al. In vitro activity of isavuconazole compared with itraconazole voriconazole and posaconazole in azole-resistant Aspergillus fumigatus [M-1377]. In: 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Denver Co 2013"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01141-13"},{"issue":"8","key":"e_1_3_3_22_1","first-page":"766","article-title":"Drug evaluation: BAL-8557\u2013a novel broad-spectrum triazole antifungal","volume":"7","author":"Odds FC","year":"2006","unstructured":"Odds FC. Drug evaluation: BAL-8557\u2013a novel broad-spectrum triazole antifungal. Curr Opin Investig Drugs 2006;7(8):766-72","journal-title":"Curr Opin Investig Drugs"},{"key":"e_1_3_3_23_1","unstructured":"Available from: http:\/\/clinicaltrials.gov"},{"key":"e_1_3_3_24_1","article-title":"Reports isavuconazole granted orphan drug designation by US FDA","volume":"57","author":"Astellas Pharma","year":"2013","unstructured":"Astellas Pharma. Reports isavuconazole granted orphan drug designation by US FDA. Clin Infect Dis 2013;57:Ii-Ii","journal-title":"Clin Infect Dis"},{"key":"e_1_3_3_25_1","volume-title":"Basilea reports that isavuconazole received QIDP designation from U.S. FDA for the treatment of invasive candidiasis","author":"Basilea Pharmaceutica","year":"2014","unstructured":"Basilea Pharmaceutica. Basilea reports that isavuconazole received QIDP designation from U.S. FDA for the treatment of invasive candidiasis. 16 edition. Basel, Switzerland: 2014. Available from: http:\/\/www.basilea.com\/News-and-Media\/"},{"key":"e_1_3_3_26_1","volume-title":"Basilea submits isavuconazole European Marketing Authorization Application for the treatment of invasive mold infections","author":"Basilea Pharmaceutica","year":"2014","unstructured":"Basilea Pharmaceutica. Basilea submits isavuconazole European Marketing Authorization Application for the treatment of invasive mold infections. 17 edition. Basilea Pharmaceutica; Basel, Switzerland: 2014. Available from: http:\/\/www.basilea.com\/News-and-Media\/"},{"key":"e_1_3_3_27_1","volume-title":"European public assessment report (EPAR) for Noxafil","author":"European Medicines Agency (EMA)","year":"2012","unstructured":"European Medicines Agency (EMA). European public assessment report (EPAR) for Noxafil. 2012"},{"key":"e_1_3_3_28_1","volume-title":"European public assessment report (EPAR) for Vfend","author":"European Medicines Agency (EMA)","year":"2012","unstructured":"European Medicines Agency (EMA). European public assessment report (EPAR) for Vfend. 2012"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00587-10"},{"key":"e_1_3_3_30_1","volume-title":"European public assessment report (EPAR) for Diflucan","author":"European Medicines Agency (EMA)","year":"2012","unstructured":"European Medicines Agency (EMA). European public assessment report (EPAR) for Diflucan. 2012"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(10)70316-9"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.4161\/viru.2.4.17074"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1086\/525258"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020191"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061094"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061098"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.2013.826989"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0000000000000005"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1086\/524071"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543780903176407"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1586\/eri.10.163"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.2.313"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.10.2883-2886.2000"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.2.441-443.2000"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1021\/ml300429p"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm9707277"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.2.384-387.2004"},{"key":"e_1_3_3_48_1","unstructured":"Efficacy Vulvovaginitis Candida. Available from: http:\/\/clinicaltrials.gov\/show\/NCT00199264"},{"key":"e_1_3_3_49_1","unstructured":"A study to evaluate efficacy and safety of three w0027 regimens in the treatment of moccasin type tinea pedis (MTTP). Available from: http:\/\/clinicaltrials.gov\/show\/NCT00509275"},{"key":"e_1_3_3_50_1","unstructured":"Efficacy and safety study of 4 dose regimens of oral albaconazole in subjects with distal subungual onychomycosis. Available from: http:\/\/clinicaltrials.gov\/show\/NCT00730405"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.39.3.954-958.2001"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/44.2.283"},{"key":"e_1_3_3_53_1","unstructured":"Bartroli X Uriach J. A clinical multicenter study comparing efficacy and tolerability between five single oral doses of albaconazole and fl uconazole 150 mg single dose in acute vulvovaginal candidiasis. In: 45th Interscience Conference on Antimicrobial Agents Chemotherapy (ICAAC). Washington DC; 2005"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-894X(02)00892-2"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.1.286-293.2006"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.1.279-285.2006"},{"key":"e_1_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.28.5.614"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0891-5520(02)00068-5"},{"key":"e_1_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.1.2.187"},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2010.02.004"},{"key":"e_1_3_3_61_1","unstructured":"Cornely OA Bohme A Reichert D et al. Pharmacokinetics safety and tolerability results from a dose escalation study of isavuconazole in neutropenic patients [M-2137]. In: 48th annual international interscience conference on antimicrobial agents and chemotherapy (ICAAC). American Society for Microbiology; Washington; 2008"},{"key":"e_1_3_3_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(07)70828-2"},{"key":"e_1_3_3_63_1","unstructured":"Schmitt-Hoffman A Roos B Roehrle M et al. No relevant food effect in man on isavuconazole oral pharmacokinetics preliminary data. In: 48th international interscience conference on antimicrobial agents and chemotherapy (ICAAC). American Society for Microbiology; Washington; 2008"},{"key":"e_1_3_3_64_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00319-09"},{"key":"e_1_3_3_65_1","doi-asserted-by":"crossref","unstructured":"Heep M Roos B Sochor M et al. QTc measurements during a placebo- and actively controlled multiple dose study of two different dosing regimen of isavuconazole [P-1675]. In: 17th annual European congress of clinical microbiology and infectious diseases (ECCMID). Munich; 2007","DOI":"10.1016\/S0924-8579(07)71514-5"},{"key":"e_1_3_3_66_1","unstructured":"Schmitt-Hoffman A Roos B Sauer J. Effect of rifampicin on the pharmacokinetics of BAL4815 at steady state after multiple oral doses of BAL8557 (WSA) and rifampicin [P-0319]. In: 16th congress of the international society for human and animal mycology (ISHAM). Paris France; 2006"},{"key":"e_1_3_3_67_1","unstructured":"Schmitt-Hoffman A Roos B Sauer J. Effect of BAL8557 a water-soluble azole pro-drug (WSA) on the pharmacokinetics of S- and R-warfarin [P-0321]. In: 16th congress of the international society for human and animal mycology (ISHAM). Paris France; 2006"},{"key":"e_1_3_3_68_1","unstructured":"Schmitt-Hoffman A Roos B Sauer J. Effect of BAL8557 a water-soluble azole pro-drug (WSA) on the pharmacokinetics of ciclosporin [P-0136]. In: 16th congress of the international society for human and animal mycology (ISHAM). Paris France; 2006"},{"key":"e_1_3_3_69_1","unstructured":"Schmitt-Hoffman A Roos B Sauer J et al. Effect of BAL8557 a Water-soluble Azole Pro-Drug (WSA) on the pharmacokinetics of Tacrolimus [P-0320]. In: 16th international society of human and animal mycoses (ISHAM). Paris France; 2006"},{"key":"e_1_3_3_70_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03779-14"},{"key":"e_1_3_3_71_1","unstructured":"Meis JF Mouton JW Bouchara JP et al. In vitro activity of isavuconazole against a worldwide collection of 237 Aspergillus section Terrei isolates and compared with 7 other Aspergillus active antifungal drugs tested with EUCAST and CLSI methodology [M-332]. In: 52rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco CA; 2012"},{"key":"e_1_3_3_72_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01190-13"},{"key":"e_1_3_3_73_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11046-014-9772-2"},{"key":"e_1_3_3_74_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00863-13"},{"key":"e_1_3_3_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2010.06.003"},{"key":"e_1_3_3_76_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01217-06"},{"key":"e_1_3_3_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2014.03.004"},{"key":"e_1_3_3_78_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01420-10"},{"key":"e_1_3_3_79_1","doi-asserted-by":"publisher","DOI":"10.1080\/13693780802562969"},{"key":"e_1_3_3_80_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01210-08"},{"key":"e_1_3_3_81_1","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2009.21.3.272"},{"key":"e_1_3_3_82_1","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12234"},{"key":"e_1_3_3_83_1","article-title":"Distributions and Epidemiological Cutoff Values for the Cryptococcus neoformans-Cryptococcus gattii Species Complex by the CLSI Broth Microdilution Method (M27-A3 document): a Multicenter Study","author":"Espinel-Ingroff A","year":"2014","unstructured":". Espinel-Ingroff A, Chowdhary A, Gonzalez GM, et al.Isavuconazole MIC. Distributions and Epidemiological Cutoff Values for the Cryptococcus neoformans-Cryptococcus gattii Species Complex by the CLSI Broth Microdilution Method (M27-A3 document): a Multicenter Study. Antimicrob Agents Chemother 2014; Epub ahead of print","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_3_84_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01384-07"},{"key":"e_1_3_3_85_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01216-08"},{"key":"e_1_3_3_86_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00646-08"},{"key":"e_1_3_3_87_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00746-10"},{"key":"e_1_3_3_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(10)70218-8"},{"key":"e_1_3_3_89_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190600741161"},{"key":"e_1_3_3_90_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.42.10.4419-4431.2004"},{"key":"e_1_3_3_91_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00685-10"},{"key":"e_1_3_3_92_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp138"},{"key":"e_1_3_3_93_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00850-13"},{"key":"e_1_3_3_94_1","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2012.208"},{"key":"e_1_3_3_95_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01000-13"},{"key":"e_1_3_3_96_1","unstructured":"Moradi PW Petraitis V Petraitiene R et al. Activity of isavuconazole amphotericin B and micafungin alone and in combination against exserohilum rostratum [M-1372]. In: 53rd interscience conference on antimicrobial agents and chemotherapy (ICAAC). Denver Co 2013"},{"key":"e_1_3_3_97_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00065-12"},{"key":"e_1_3_3_98_1","doi-asserted-by":"publisher","DOI":"10.1080\/02681219480000951"},{"key":"e_1_3_3_99_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00019-10"},{"key":"e_1_3_3_100_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00239744"},{"key":"e_1_3_3_101_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03095-14"},{"key":"e_1_3_3_102_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01629-13"},{"key":"e_1_3_3_103_1","first-page":"102","article-title":"Antifungal activity of isavuconazole and 7 other drugs against Cladophialophora spp., related to chromoblastomycosis","volume":"52","author":"Badali H","year":"2009","unstructured":"Badali H, De Hoog GS, Curfs-Breuker I, Meis JF. Antifungal activity of isavuconazole and 7 other drugs against Cladophialophora spp., related to chromoblastomycosis. Mycoses 2009;52:102-3","journal-title":"Mycoses"},{"key":"e_1_3_3_104_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02114-12"},{"key":"e_1_3_3_105_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01112-12"},{"key":"e_1_3_3_106_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01170-12"},{"key":"e_1_3_3_107_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05910-11"},{"key":"e_1_3_3_108_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc061720"},{"key":"e_1_3_3_109_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01551-06"},{"key":"e_1_3_3_110_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01952-07"},{"key":"e_1_3_3_111_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks189"},{"key":"e_1_3_3_112_1","doi-asserted-by":"publisher","DOI":"10.1086\/423274"},{"key":"e_1_3_3_113_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.44.2.529-535.2006"},{"key":"e_1_3_3_114_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.11.2753"},{"key":"e_1_3_3_115_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.2.668-679.2005"},{"key":"e_1_3_3_116_1","unstructured":"Sanglard D Ischer F Coste A Rerrari S. Comparison between isavuconazole (ISA) and other azoles against characterized clinical isolates and yeast model systems [P-2176]. In: 18th European congress of clinical microbiology and infectious diseases (ECCMID). Barcelona; 2008"},{"key":"e_1_3_3_117_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01355-13"},{"key":"e_1_3_3_118_1","unstructured":"Seyedmousavi S Meis JF Bruggemann RJ et al. Pharmacodynamics of the new azole isavuconazole in an Aspergillus fumigatus mouse infection model [P1698]. In: 23rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Baecelona; 2014"},{"key":"e_1_3_3_119_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl396"},{"key":"e_1_3_3_120_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01354-13"},{"key":"e_1_3_3_121_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01601-08"},{"key":"e_1_3_3_122_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn431"},{"key":"e_1_3_3_123_1","unstructured":"Te Dorsthorst DT Verweij PE Meis JF Mouton JW. Pharmacodynamics of BAL4815 a new azole antifungal in a mouse model of systemic infection [A\u20131874]. In: 14th European Congress of Clinical Microbiology and Infectious Diseases (ESCMID). Prague Czech Republic; 2004"},{"key":"e_1_3_3_124_1","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-013-0552-6"},{"key":"e_1_3_3_125_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02301-13"},{"key":"e_1_3_3_126_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.03176-13"},{"key":"e_1_3_3_127_1","unstructured":"Isavuconazole (BAL8557) for primary treatment of invasive aspergillosis. Available from: http:\/\/clinicaltrials.gov\/show\/NCT00412893"},{"key":"e_1_3_3_128_1","unstructured":"Maertens J Patterson T Rahav G et al. A phase 3 randomised double \u2013binded trial evaluating isavuconazole vs. voriconazole for the primary treatment of invasive fungal disease caused by Aspergillus spp. or other filamentous fungi (SECURE) [O230a]. In: 23rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Barcelona; 2013"},{"key":"e_1_3_3_129_1","unstructured":"Isavuconazole in the treatment of renally impaired aspergillosis and rare fungi (VICAL). Available from: http:\/\/clinicaltrials.gov\/show\/NCT00634049"},{"key":"e_1_3_3_130_1","unstructured":"Isavuconazole (BAL8557) in the treatment of candidemia and other invasive candida infections. Available from: http:\/\/clinicaltrials.gov\/show\/NCT00413218"}],"container-title":["Expert Review of Anti-infective Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1586\/14787210.2015.990382","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T18:31:48Z","timestamp":1770402708000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1586\/14787210.2015.990382"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,8]]},"references-count":129,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1,2]]}},"alternative-id":["10.1586\/14787210.2015.990382"],"URL":"https:\/\/doi.org\/10.1586\/14787210.2015.990382","relation":{},"ISSN":["1478-7210","1744-8336"],"issn-type":[{"value":"1478-7210","type":"print"},{"value":"1744-8336","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,8]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierz20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierz20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2014-12-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}